Neumora Therapeutics Announces Favorable Preclinical Toxicology for NMRA-215

What Happened Neumora Therapeutics, Inc. announced on July 27, 2026 (via a press release filed as Exhibit 99.1 to a Form 8‑K) that it received favorable pre-clinical toxicology results for its development candidate NMRA-215. The 8‑K was signed by CFO Michael Milligan and incorporates the press release by reference.

Key Details

• Event filed: Current Report on Form 8‑K dated July 27, 2026 (Item 8.01 — Other Events).
• Subject: Favorable pre-clinical toxicology results for NMRA-215 announced in a July 27, 2026 press release (Exhibit 99.1).
• Administrative: The report was signed on behalf of Neumora by Michael Milligan, Chief Financial Officer.

Why It Matters Favorable pre-clinical toxicology is a positive milestone in a drug development program because it addresses safety signals before human testing. For investors, this development is a factual progress point for NMRA-215’s preclinical program and may be required before submitting IND-enabling packages or advancing to clinical trials. The Form 8‑K confirms the company’s public disclosure of these results but does not include additional data or timelines; investors should look to Neumora’s press release and future filings for detailed study results and next steps.